Others have previously shown that high Oncostatin M (OSM) expression in patients with IBD is associated with failure to anti-TNF therapy and that high expression of its receptor is found in intestinal stromal cells, suggesting that mesenchymal cells have a significant role in IBD patient heterogeny to respond to anti-TNF agents [2]. The gene discussed is OSM; the disease is inflammatory bowel disease.